Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

Phase 3

Completed

Conditions: Macular Edema
Central Retinal Vein Occlusion

Interventions: Drug: Ranibizumab 0.5 mg/0.05 ml

First Posted Date: 2012-02-17

Last Posted Date: 2016-10-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 357

Registration Number: NCT01535261

Locations: 🇬🇧
Novartis Investigative Site, Southampton, United Kingdom

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)

Phase 4

Completed

Conditions: Relapsing Remitting Multiple Sclerosis

Interventions: Drug: Interferon beta - 1a (IFN)
Drug: Fingolimod
Drug: Glatiramer acetate (GA)

First Posted Date: 2012-02-16

Last Posted Date: 2014-08-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 298

Registration Number: NCT01534182

Locations: 🇷🇺
Novartis Investigative Site, Yaroslavl, Russian Federation

Continuation Study of the Oral AKT Inhibitor GSK2110183

Phase 2

Completed

Conditions: Cancer

Interventions: Drug: GSK2110183 (afuresertib)

First Posted Date: 2012-02-13

Last Posted Date: 2019-07-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 11

Registration Number: NCT01531894

Locations: 🇰🇷
Novartis Investigative Site, Seoul, Korea, Republic of

Pharmacokinetics of AGO178 in Participants With Liver Impairment

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: AGO178

First Posted Date: 2012-02-10

Last Posted Date: 2021-05-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 32

Registration Number: NCT01531309

Locations: 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

Phase 4

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Rivastigmine transdermal patch

First Posted Date: 2012-02-09

Last Posted Date: 2016-11-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 52

Registration Number: NCT01529619

Locations: 🇯🇵
Novartis Investigative Site, Kyoto, Japan

Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: QVA149
Drug: NVA237
Drug: Placebo
Drug: QAB149

First Posted Date: 2012-02-09

Last Posted Date: 2014-02-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 193

Registration Number: NCT01529632

Locations: 🇸🇪
Novartis Investigative Site, Uddevalla, Sweden

First in Human Trial of TAS266 in Patients With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Advanced Solid Tumors

Interventions: Drug: TAS266

First Posted Date: 2012-02-08

Last Posted Date: 2020-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 6

Registration Number: NCT01529307

Locations: 🇺🇸
South Texas Accelerated Research Therapeutics START, San Antonio, Texas, United States
🇺🇸
University of Utah / Huntsman Cancer Institute Huntsman UT, Salt Lake City, Utah, United States
🇺🇸
H. Lee Moffitt Cancer Center/University of South Florida Moffitt SC, Tampa, Florida, United States

Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer

Phase 2

Terminated

Conditions: Metastatic Breast Cancer

Interventions: Drug: Dovitinib
Drug: Dovitinib Placebo
Drug: Fulvestrant

First Posted Date: 2012-02-08

Last Posted Date: 2016-07-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 97

Registration Number: NCT01528345

Locations: 🇺🇸
City of Hope National Medical Center COH 3, Duarte, California, United States
🇺🇸
University of California San Diego - Moores Cancer Center Moores UCSD Cancer Ctr. SC-1, La Jolla, California, United States
🇺🇸
ProHealth Care, Lake Success, New York, United States

and more 16 locations

Single-dose Iloperidone Pharmacokinetics in Patients With Mild or Moderate Liver Disease, Compared to Healthy Volunteers

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Iloperidone

First Posted Date: 2012-02-08

Last Posted Date: 2013-03-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 90

Registration Number: NCT01529294

Locations: 🇺🇸
Novartis Investigative Site, South Miami, Florida, United States

Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)

Phase 2

Completed

Conditions: Geographic Atrophy
Age-related Macular Degeneration

Interventions: Drug: LFG316
Drug: Sham
Drug: LFG316 Lower dose

First Posted Date: 2012-02-07

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 158

Registration Number: NCT01527500

Locations: 🇺🇸
Novartis Investigative Site, Silverdale, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy